TY - JOUR
T1 - Antimullerian hormone and obesity
T2 - insights in oral contraceptive users
AU - Steiner, Anne Z.
AU - Stanczyk, Frank Z.
AU - Patel, Stan
AU - Edelman, Alison
N1 - Funding Information:
Financial support: HD 01243-03 Women's Reproductive Health Research Fellow (NICHD K-12), PHS Grant 5 M01 RR000334, 1 R03 HD 053611-01, UNC WRHR HD 050113-02 and the University of North Carolina: University Research Council Grant.
PY - 2010/3
Y1 - 2010/3
N2 - Background: The study was conducted to examine the impact of oral contraceptives (OCs) on serum antimullerian hormone (AMH) levels by obesity status in reproductive-age women. Study Design: Ovulatory women, ages 18-35 years, of normal (<25 kg/m2; n=10) and obese (>30 kg/m2; n=10) body mass index (BMI) received a low-dose OC (20 mcg ethinyl estradiol/100 mcg levonorgestrel) for two cycles. Serum samples obtained at several time points during active pill use and hormone-free intervals were analyzed for AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and inhibin B. Results: AMH levels did not differ by OC cycle day in either BMI group. On average, AMH levels were 34% lower in the obese group (2.9±2.1 vs. 4.4±1.8 ng/mL, p<.05). Modeling to determine differences in AMH throughout the cycle based on obesity status demonstrated significantly lower levels (p<.05), whereas serum AMH, FSH, LH, estradiol and inhibin B levels revealed no correlations when all time points were included. Conclusions: In reproductive-age women, serum AMH levels do not appear to fluctuate during OC use, but AMH levels are significantly lower in obese women. Lower levels do not appear to be due to differences in gonadotropin levels or ovarian activity.
AB - Background: The study was conducted to examine the impact of oral contraceptives (OCs) on serum antimullerian hormone (AMH) levels by obesity status in reproductive-age women. Study Design: Ovulatory women, ages 18-35 years, of normal (<25 kg/m2; n=10) and obese (>30 kg/m2; n=10) body mass index (BMI) received a low-dose OC (20 mcg ethinyl estradiol/100 mcg levonorgestrel) for two cycles. Serum samples obtained at several time points during active pill use and hormone-free intervals were analyzed for AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and inhibin B. Results: AMH levels did not differ by OC cycle day in either BMI group. On average, AMH levels were 34% lower in the obese group (2.9±2.1 vs. 4.4±1.8 ng/mL, p<.05). Modeling to determine differences in AMH throughout the cycle based on obesity status demonstrated significantly lower levels (p<.05), whereas serum AMH, FSH, LH, estradiol and inhibin B levels revealed no correlations when all time points were included. Conclusions: In reproductive-age women, serum AMH levels do not appear to fluctuate during OC use, but AMH levels are significantly lower in obese women. Lower levels do not appear to be due to differences in gonadotropin levels or ovarian activity.
KW - Antimullerian hormone
KW - Obesity
KW - Oral contraceptives
UR - http://www.scopus.com/inward/record.url?scp=76049129852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76049129852&partnerID=8YFLogxK
U2 - 10.1016/j.contraception.2009.10.004
DO - 10.1016/j.contraception.2009.10.004
M3 - Article
C2 - 20159182
AN - SCOPUS:76049129852
SN - 0010-7824
VL - 81
SP - 245
EP - 248
JO - Contraception
JF - Contraception
IS - 3
ER -